<DOC>
	<DOCNO>NCT01563302</DOCNO>
	<brief_summary>This Phase 1/2 , open-label , dose-escalation , dose-expansion study treatment patient advance cancer . Eligible patient DLBCL advance lymphoma enrol dose-expansion cohort .</brief_summary>
	<brief_title>Phase 1/2 , Open-label , Dose-escalation Study IONIS-STAT3Rx , Administered Patients With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Aged 18 year old Tumors relapse refractory least 1 prior anticancer systemic therapy standard therapy exist Expansion cohort : Advanced lymphoma confirm histopathology Measurable evaluable disease accord RECIST solid tumor accord IWRC NHL tumor ECOG Performance Status less equal 2 Life expectancy great 12 week opinion Investigator Any active uncontrolled infection NYHA Grade II great congestive heart failure History myocardial infarction within 6 month prior screen Prior radiation therapy , chemotherapy , hormonal therapy , immunotherapy within 4 week prior screen 5 halflives therapy , whichever short</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Advanced Lymphoma</keyword>
</DOC>